2023 World Conference on Lung Cancer (Posters)-P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab

P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab - PDF(Slides)

Back to course

Pdf Summary

The Scottish Inflammatory Prognostic Score (SIPS) has been found to be a statistically significant prognostic biomarker in patients with advanced lung cancer treated with Pembrolizumab. The study analyzed a database of 250 patients and found that the median survival decreased from 21.7 months (SIPS0), to 12.4 months (SIPS1), to 3.1 months (SIPS2). SIPS was shown to be a significant predictor of survival outcomes regardless of the patients’ performance status (PS). Patients with a combination of PS score of 2 and SIPS score of 2 had a poor survival outcome and derived little benefit from treatment. The researchers highlight that both PS and SIPS scores are easily available and use routinely taken markers. They advocate for further studies on the relationship between PS and SIPS and their impact on survival outcomes to guide treatment decisions for this patient population. The findings suggest that by considering SIPS as a biomarker in combination with PS, it may help better predict patient survival.

Asset Subtitle

Samantha Low

Meta Tag

Speaker Samantha Low

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

Scottish Inflammatory Prognostic Score

SIPS

prognostic biomarker

advanced lung cancer

Pembrolizumab

median survival

performance status

survival outcomes

treatment decisions

patient survival